JP2004507446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507446A5 JP2004507446A5 JP2001556500A JP2001556500A JP2004507446A5 JP 2004507446 A5 JP2004507446 A5 JP 2004507446A5 JP 2001556500 A JP2001556500 A JP 2001556500A JP 2001556500 A JP2001556500 A JP 2001556500A JP 2004507446 A5 JP2004507446 A5 JP 2004507446A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tumor
- tumor cell
- tumor cells
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 47
- 210000004881 tumor cells Anatomy 0.000 description 30
- 239000000284 extract Substances 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 8
- 210000004027 cells Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 229960004397 Cyclophosphamide Drugs 0.000 description 4
- 206010025650 Malignant melanoma Diseases 0.000 description 4
- 230000000259 anti-tumor Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- VOTFXKJPNQELOG-UHFFFAOYSA-N arsenic acid Chemical compound O[As](=O)=O VOTFXKJPNQELOG-UHFFFAOYSA-N 0.000 description 2
- 229940000488 arsenic acid Drugs 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- -1 dinitrophenyl Chemical group 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulators Drugs 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N Sulfanilic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HIVRRMRPNKBZDM-UHFFFAOYSA-N [N-]=C=S.C1=CC=CC=C1 Chemical compound [N-]=C=S.C1=CC=CC=C1 HIVRRMRPNKBZDM-UHFFFAOYSA-N 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UATJOMSPNYCXIX-UHFFFAOYSA-N symmetric Trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UATJOMSPNYCXIX-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18025800P | 2000-02-04 | 2000-02-04 | |
| US25950100P | 2001-01-03 | 2001-01-03 | |
| PCT/US2001/003448 WO2001056601A2 (fr) | 2000-02-04 | 2001-02-02 | Immunotherapie utilisant des cellules tumorales haptenisees et des extraits de cellules tumorales a faible dose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507446A JP2004507446A (ja) | 2004-03-11 |
| JP2004507446A5 true JP2004507446A5 (fr) | 2008-03-13 |
Family
ID=32033187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001556500A Pending JP2004507446A (ja) | 2000-02-04 | 2001-02-02 | 低用量ハプテン化腫瘍細胞および腫瘍細胞抽出物の免疫治療 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004507446A (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1841450A4 (fr) * | 2005-01-14 | 2013-04-17 | Avax Technologies Inc | Methode de production d'un vaccin pour le traitement du cancer |
| EP1984004A4 (fr) * | 2006-01-17 | 2010-03-03 | Sloan Kettering Inst Cancer | Glucane permettant d'améliorer une thérapie |
| FR3011850B1 (fr) * | 2013-10-15 | 2018-04-06 | Cfl Biotech | Vaccin therapeutique contre le cancer a base de proteines de stress rendues immunogenes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002502880A (ja) * | 1998-02-17 | 2002-01-29 | トーマス・ジェファーソン・ユニバーシティ | ハプテン改変化腫瘍細胞膜およびその使用 |
| AR020067A1 (es) * | 1998-04-09 | 2002-04-10 | Univ Jefferson | Uso y composicion para inducir una respuesta anti-tumoral contra una metastasis de melanoma |
| EP1082134B1 (fr) * | 1998-05-04 | 2008-07-16 | Thomas Jefferson University | L'utilisation des cellules tumorales et des extraits des tumeurs traitant d'un haptène |
-
2001
- 2001-02-02 JP JP2001556500A patent/JP2004507446A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006312013B2 (en) | Concurrent chemotherapy and immunotherapy | |
| EP1594524B1 (fr) | Utilisation de composes de tryptanthrine dans la potentialisation immunologique | |
| AR004445A1 (es) | Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada | |
| JP2002531521A5 (fr) | ||
| Mokyr et al. | Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide | |
| KR100392582B1 (ko) | 면역치료제및이의용도 | |
| HUP9901254A2 (hu) | Nemdendrites szerkezetű gerincet alkotó peptid hordozó | |
| JP2000515127A (ja) | 脳腫瘍の再発の治療および予防のためのｇｍ―ｃｓｆ投与 | |
| KR20010030649A (ko) | 알파-글리코실세라미드를 함유하는 세포 면역원성 증강용조성물 | |
| EP1723963A3 (fr) | Cellules tumorales hapténisées | |
| ES2424011T3 (es) | Tratamiento de las metástasis tumorales y el cáncer | |
| RU2002128917A (ru) | Полиаминные аналоги в качестве цитотоксических агентов | |
| Hattori et al. | Five-year survival rate of gastric cancer patients treated by gastrectomy, large dose of mitomycin-C, and/or allogeneic bone marrow transplantation | |
| JP2004507446A5 (fr) | ||
| CA2354045A1 (fr) | Nouveaux traitements contre le cancer | |
| JP2002531520A5 (fr) | ||
| Bocci | Ozontherapy as a Possible Biological Response Modifier in Cancer | |
| Splinter et al. | Phase I study of alpha-difluoromethylornithine and methyl-GAG | |
| RU2379055C1 (ru) | Способ лечения онкологических заболеваний | |
| Tanaka et al. | Effect of immunotherapy, chemotherapy, and surgery on tumor immunity in mice | |
| US6916845B2 (en) | Method for prevention and treatment of male and female sexual dysfunction | |
| WO2001043771A1 (fr) | Utilisation de proteines immunogenes immunosuppressives ou angiogeniques rendues inactives pour la production d'iga secretoires | |
| MD2355G2 (ro) | Metodă de pregătire preimplantare | |
| WO2003035104B1 (fr) | Compositions et procedes de traitement de tumeur selectionnee | |
| RU2004101182A (ru) | Способ предоперационного лечения рака молочной железы |